Skip to main content

BGG from China opens headquarters in Basel

| News

BGG from China opens headquarters in Basel


BGG is establishing new global headquarters in Basel, from which it plans to grow in Europe and the USA. The Beijing-based company is a supplier of clinically tested, natural ingredients used in food, drinks, pharmaceuticals, animal food and cosmetics.

The new BGG headquarters in Basel is headed by CEO Jürgen Nelis (image: BGG)

BGG, family-owned company based in Beijing, is opening its new global headquarters in Basel, from which it will operate under the name BGG World. The newly appointed CEO is Jürgen Nelis, with Thomas Adler also joining the company in the role of Global Commercial Director. From its base in Basel, BGG intends to secure growth on the European and US markets. BaselArea Business & Innovation supported BGG in the process of settling in Basel.

According to information from the investment and innovation promotion agency, the central location in Europe, the economic and political stability offered by Switzerland, as well as the country’s numerous free trade agreements, were crucial pull factors in favor of establishing the new headquarters in Basel. Moreover, risks will also be reduced in the global supply chain, as the supplier of high-quality, natural and non-GMO ingredients writes in a press release.

Cooperations with domestic industrial partners

“We strongly believe that our three leading technology platforms – botanical extraction, enzymatic conversion, and micro-algae farming – combined with continuous investment in clinical trials, will provide our customers with high-value, sustainable business potential for the long-term future”, comments Chunhua Li, founder and principal shareholder of BGG, in the press release. Jürgen Nelis, CEO of BGG World, also confirms the expansions plans: “As we internationalize our organizational structure and operating model, we will be investing heavily in our commercial organization”.

At the same time, financial resources will be made available for human clinical trials involving BGG’s core products, Nelis explains. Cooperations with several domestic industrial partners and a research institute have already been initiated. Moreover, BGG is currently hiring several sales managers in Europe and the USA so as to “double our customer-facing resources in these key markets”, as Nelis adds.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.